RESUMO
Photodynamic therapy is an approved treatment for primary, superficial, and small nodular basal cell carcinomas with a thickness of < 2 mm located on low-risk sites. Histologically verified basal cell carcinomas clinically assessed as suited for photodynamic therapy were included. The study aimed to investigate the agreement between clinical and histological assessments of basal cell carcinoma subtypes and thickness of tumours selected for photodynamic therapy with histopathological evaluation as a reference. A total of 343 tumours were included. The agreement between clinical and histological diagnosis of basal cell carcinoma subtype was 72% (p < 0.001). Clinical assessment of subtype had a sensitivity of 93% and specificity of 55% for superficial tumours and a sensitivity of 55% and specificity of 85% for nodular tumours. The mean ± SD thickness values by clinical and histological assessments were 0.95 ± 0.53 and 0.86 ± 0.75. The difference of 0.09 mm was statistically significant (p = 0.017), but not considered to be clinically relevant, although the differences between specific subgroups could be relevant. Among basal cell carcinomas clinically diagnosed as superficial, 91% were histologically consistent with the current photodynamic therapy criteria. The main results suggest that histopathological evaluation should precede photodynamic therapy to ensure selection of suitable basal cell carcinomas. In selected cases, the clinical diagnosis alone may be adequate before proceeding with photodynamic therapy.
Assuntos
Carcinoma Basocelular , Fotoquimioterapia , Neoplasias Cutâneas , Humanos , Carcinoma Basocelular/patologia , Carcinoma Basocelular/tratamento farmacológico , Neoplasias Cutâneas/patologia , Neoplasias Cutâneas/tratamento farmacológico , Masculino , Feminino , Idoso , Pessoa de Meia-Idade , Idoso de 80 Anos ou mais , Valor Preditivo dos Testes , Biópsia , Adulto , Seleção de Pacientes , Fármacos Fotossensibilizantes/uso terapêutico , Estudos RetrospectivosRESUMO
In Norway, nodular melanoma is the most fatal melanoma subtype and superficial spreading melanoma the most common, indicating diagnostic challenges. The aim of this study was to assess the clinical suspicion sensitivity of nodular melanoma and superficial spreading melanoma, by diagnosing physician, using randomly selected 100 nodular melanomas and 100 superficial spreading melanomas from the Norwegian Melanoma Registry, diagnosed in 2014 to 2015. Information about suggested diagnoses and diagnosing physician was collected from pathology request forms. Suspicion sensitivity was defined as the proportion (%) of cases with "melanoma" as a suggested diagnosis, estimated with 95% confidence interval (95% CI). Most melanomas (74.5%) were diagnosed by non-dermatologists, with a suspicion sensitivity of 23% (95% CI 15-34) for nodular melanoma and 24% (95% CI 16-35) for superficial spreading melanoma. Corresponding estimates for dermatologists were 50% (95% CI 32-68) and 96% (95% CI 80-99), respectively (pinteraction=0.007). The low suspicion sensitivity for both subtypes among non-dermatologists calls for educational efforts.
Assuntos
Melanoma , Neoplasias Cutâneas , Humanos , Melanoma/diagnóstico , Noruega/epidemiologia , Sistema de Registros , Neoplasias Cutâneas/diagnósticoRESUMO
BACKGROUND: Errors in Breslow thickness reporting can give misclassification of T category, an important classifier in melanoma staging. OBJECTIVE: We sought to investigate precision (number of digits) and terminal digit clustering in Breslow thickness and potential consequences for T category. METHODS: All first primary and morphologically verified invasive melanomas in Norway between 2008 and 2015 were included. A smoothing model was fitted to estimate the underlying Breslow thickness distribution without digit clustering. RESULTS: Thickness was reported for 13,057 (97.5%) patients; the median was 1.0 mm (range, 0.09-85). It was reported as whole numbers (15.6%), to 1 decimal (78.2%) and 2 decimal places (6.2%)-thin tumors with more precision than thick tumors. Terminal digit clustering was found with marked peaks in the observed frequency distribution for terminal digits 0 and 5, and with drops around these peaks. Terminal digit clustering increased proportions of patients classified with T1 and T4 tumors and decreased proportions classified with T2 and T3. LIMITATIONS: Breslow thickness was not reported in 2.5% of cases. CONCLUSIONS: The Norwegian recommendation of measurement to the nearest 0.1 mm was not followed. Terminal digit clustering was marked, with consequences for T category. Pathologists, clinicians, and epidemiologists should know that clustering of thickness data around T category cut points can impact melanoma staging with consequent effect on patient management and prognosis.
Assuntos
Melanoma/epidemiologia , Melanoma/patologia , Estadiamento de Neoplasias/métodos , Sistema de Registros , Neoplasias Cutâneas/patologia , Adulto , Idoso , Biópsia por Agulha , Análise por Conglomerados , Estudos de Coortes , Feminino , Humanos , Imuno-Histoquímica , Incidência , Masculino , Melanoma/classificação , Pessoa de Meia-Idade , Invasividade Neoplásica/patologia , Noruega/epidemiologia , Vigilância da População , Estudos Retrospectivos , Medição de Risco , Neoplasias Cutâneas/classificação , Neoplasias Cutâneas/epidemiologia , Adulto Jovem , Melanoma Maligno CutâneoRESUMO
Folliculotropic mycosis fungoides (FMF), a variant of mycosis fungoides (MF) with distinct clinical features, is characterized by infiltration of malignant T cells in hair follicles. This raises the hypothesis that antigens in the hair follicle may contribute to the pathogenesis of FMF. T-cell receptor ß gene (TRB) sequences as well as dendritic cell subsets in patients with FMF (n = 21) and control patients with MF (n = 20) were studied to explore this hypothesis. A recurrent usage of the TRB junctional genes TRBJ2-1 and TRBJ2-7 was found in patients with FMF compared with those with MF. These genes contribute to an amino acid motif in the complementarity-determining region 3 (CDR3) of the T-cell receptor. This motif was previously found in T cells stimulated by lipids bound to CD1 on antigen-presenting cells. Additional immunohistochemical analysis revealed abundant CD1c- and CD1a- expressing dendritic cells in FMF. The combined findings support a role for lipid-antigen stimulation in FMF.
Assuntos
Antígenos CD1/análise , Glicoproteínas/análise , Micose Fungoide/química , Micose Fungoide/patologia , Estudos de Casos e Controles , Regiões Determinantes de Complementaridade/análise , Células Dendríticas/química , Genes Codificadores da Cadeia beta de Receptores de Linfócitos T , Folículo Piloso/química , Folículo Piloso/patologia , Humanos , Imuno-Histoquímica , Linfoma Cutâneo de Células T/química , Linfoma Cutâneo de Células T/genética , Linfoma Cutâneo de Células T/patologia , Micose Fungoide/genética , Neoplasias Cutâneas/química , Neoplasias Cutâneas/genética , Neoplasias Cutâneas/patologiaRESUMO
BACKGROUND: Most studies of cutaneous head and neck melanomas (CHNM) have reported poorer survival in CHNM compared with other sites, especially on the scalp/neck. OBJECTIVE: We sought to compare patient and tumor characteristics between CHNM and cutaneous trunk and extremity melanomas and between CHNM locations (face/ear vs scalp/neck, anterior vs posterior), and to study prognostic factors in patients with CHNM. METHODS: We studied all CHNM (n = 1074) from 8120 cases of cutaneous melanomas diagnosed in Norway in 2008 to 2012. RESULTS: Compared with cutaneous trunk and extremity melanomas, CHNM were more frequently found in men, more often nodular and lentigo maligna cutaneous melanomas, and diagnosed at higher T stage (P ≤ .01). CHNM located on posterior sites were diagnosed at significantly higher T stage, and were significantly more often diagnosed with ulceration and at more advanced stage compared with CHNM located on anterior sites (P < .001). T stage and clinical stage were the only significant prognostic factors for melanoma-specific and overall death in the multivariable analysis (P < .001). LIMITATIONS: Low number of cases and the relatively high frequency of missing values are limitations. CONCLUSION: More advanced CHNM were diagnosed on posterior compared with anterior locations, but location was not a significant prognostic factor for cutaneous melanoma-specific or overall death in the multivariable models.
Assuntos
Melanoma/mortalidade , Neoplasias Cutâneas/microbiologia , Adulto , Idoso , Extremidades , Feminino , Neoplasias de Cabeça e Pescoço/mortalidade , Humanos , Sarda Melanótica de Hutchinson/mortalidade , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Noruega/epidemiologia , Especificidade de Órgãos , Prognóstico , Sistema de Registros , Tronco , Melanoma Maligno CutâneoRESUMO
At least 17 genomic regions are established as harboring melanoma susceptibility variants, in most instances with genome-wide levels of significance and replication in independent samples. Based on genome-wide single nucleotide polymorphism (SNP) data augmented by imputation to the 1,000 Genomes reference panel, we have fine mapped these regions in over 5,000 individuals with melanoma (mainly from the GenoMEL consortium) and over 7,000 ethnically matched controls. A penalized regression approach was used to discover those SNP markers that most parsimoniously explain the observed association in each genomic region. For the majority of the regions, the signal is best explained by a single SNP, which sometimes, as in the tyrosinase region, is a known functional variant. However in five regions the explanation is more complex. At the CDKN2A locus, for example, there is strong evidence that not only multiple SNPs but also multiple genes are involved. Our results illustrate the variability in the biology underlying genome-wide susceptibility loci and make steps toward accounting for some of the "missing heritability."
Assuntos
Predisposição Genética para Doença , Melanoma/genética , Polimorfismo de Nucleotídeo Único , Mapeamento Cromossômico , Ciclina D1/genética , Inibidor p16 de Quinase Dependente de Ciclina/genética , Loci Gênicos , Humanos , Telomerase/genéticaRESUMO
A few key publications report on the frequency of skin disorders in paediatric organ transplant recipients in Southern and Central Europe presenting cumulative incidences. We aimed to estimate frequencies of skin disorders both as cumulative incidences and prevalence data, and describe skin problems in paediatric renal transplant recipients in a Norwegian renal transplant population. Clinical examination and review of post-transplant skin diseases were conducted in 70 patients having performed renal transplantation before the age of 16 in the period 1983-2006. Viral warts were a common and persistent problem, whereas bacterial and fungal infections in the skin were few. Drug-related skin disorders were rather frequent, but usually reversible on dose reduction or change of medication. Pre-malignant and malignant skin disorders appeared only in patients > 30 years of age. Relatively high cumulative incidences and low prevalence data of most skin disorders were found in the examined patient cohort.
Assuntos
Transplante de Rim/efeitos adversos , Dermatopatias/epidemiologia , Adolescente , Adulto , Fatores Etários , Criança , Pré-Escolar , Estudos Transversais , Feminino , Humanos , Incidência , Masculino , Noruega/epidemiologia , Prevalência , Sistema de Registros , Fatores de Risco , Dermatopatias/diagnóstico , Fatores de Tempo , Adulto JovemRESUMO
The main purpose of this study was to compare the effect of the 2 minimally invasive surgical techniques for treating axillary hyperhidrosis: superficial tumescent suction curettage and curettage only. A total of 22 patients diagnosed with axillary hyperhidrosis received one type of treatment at each side, randomized. Examinations were performed pre-operatively and at 3, 6 and 12 months following treatment. Sweating was measured by gravimetry and a new skin conductance method. Subjective rating of sweating was assessed by a visual analogue scale. Skin conductance was recorded during a stress-test including acoustic, mental and physical stressors. Five patients withdrew or did not meet for any follow-up examination, giving 17 subjects in total for data analysis. Significant reduction in sweating after surgery lasting at least 12 months was found based on skin conductance, gravimetry and visual analogue scale scoring. Comparison between types of treatment revealed a significantly better effect of tumescent suction curettage than curettage only.
Assuntos
Axila/cirurgia , Curetagem , Hiperidrose/cirurgia , Lipectomia , Glândulas Sudoríparas/cirurgia , Adulto , Feminino , Seguimentos , Resposta Galvânica da Pele , Humanos , Masculino , Qualidade de Vida , Distribuição Aleatória , Escala Visual Analógica , Adulto JovemRESUMO
Multiple distinct T-cell clones have been demonstrated in a subset of mycosis fungoides (MF), but have so far not been documented in folliculotropic MF, a clinical and histological variant of MF. We analyzed T-cell receptor (TCR) gene rearrangements in 8 patients with folliculotropic MF with multiple biopsies (range, 2-5) taken during the course of disease. Two patients had disease stage IA-IIA, 5 stage IIB-IVA, whereas data were not available for 1 patient. TCR ß and γ gene rearrangements were analyzed according to the BIOMED-2 PCR protocol. Multiple clonal TCR gene rearrangements indicating more than 1 T-cell clone were found in 5 patients. Although the number of patients is small, the finding of multiple distinct T-cell clones in 5 out of 8 patients suggests that chronic T-cell stimulation contributes to the development of folliculotropic MF.
Assuntos
Rearranjo Gênico da Cadeia beta dos Receptores de Antígenos dos Linfócitos T , Rearranjo Gênico da Cadeia gama dos Receptores de Antígenos dos Linfócitos T , Micose Fungoide/genética , Micose Fungoide/patologia , Adulto , Idoso , Células Clonais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Micose Fungoide/imunologiaRESUMO
BACKGROUND: Topical photodynamic therapy (PDT) is an approved and widely used treatment for low-risk basal cell carcinoma (BCC), comprising two sessions with an interval of 1 week. Simplification of the treatment course can be cost-effective, easier to organize, and cause less discomfort for the patients. METHODS AND FINDINGS: We performed an investigator-initiated, single-blind, non-inferiority, randomized controlled multicentre study with the objective of investigating whether a simpler and more flexible PDT regimen was not >10% less effective than the standard double PDT in the treatment of primary, superficial, and nodular ≤2 mm-thick BCC and evaluate the cosmetic outcome. With a non-inferiority margin of 0.1 and an expected probability complete response of 0.85, 190 tumours were required in each group. Histologically verified BCCs from seven centres in Norway were randomly assigned (1:1) to either receive a new regimen of single PDT with one possible re-treatment of non-complete responding tumours, or the standard regimen. The primary endpoint was the number of tumours with complete response or treatment failure at 36 months of follow-up, assessed by investigators blinded to the treatment regimen. Intention-to-treat and per-protocol analyses were performed. The cosmetic outcome was recorded. The study was registered with ClinicalTrials.gov, NCT-01482104, and EudraCT, 2011-004797-28. A total of 402 BCCs in 246 patients were included; 209 tumours assigned to the new and 193 to the standard regimen. After 36 months, there were 61 treatment failures with the new and 34 failures with the standard regimen. Complete response rate was 69.5% in the new and 81.1% in the standard treatment group. The difference was 11.6% (upper 97.5% CI 20.3), i.e. > than the non-inferiority margin of 10%. Cosmetic outcomes were excellent or good in 92% and 89% following the new and standard regimens, respectively. CONCLUSIONS: Single PDT with possible re-treatment of primary, superficial, and nodular ≤ 2-mm-thick BCC was significantly less effective than the approved standard double treatment. The cosmetic outcome was favorable and comparable between the two treatment groups.
Assuntos
Carcinoma Basocelular , Fotoquimioterapia , Neoplasias Cutâneas , Humanos , Neoplasias Cutâneas/patologia , Fármacos Fotossensibilizantes/uso terapêutico , Ácido Aminolevulínico/uso terapêutico , Método Simples-Cego , Carcinoma Basocelular/patologia , Resposta Patológica Completa , Resultado do TratamentoRESUMO
Folliculotropic mycosis fungoides is a variant of cutaneous T-cell lymphoma with distinct clinicopathological features. We describe here the clinical presentation, pathology findings and treatment outcome in 15 Norwegian patients. All patients were diagnosed between 1997 and 2010 at Oslo University Hospital. A spectrum of skin lesions, both typical and atypical, such as leonine facies, acneiform lesions, psoriasiform plaques, purulent ulcerations and cystic milia-like lesions for mycosis fungoides, were seen. Histological examination revealed characteristic infiltration of hair follicles with neoplastic T cells associated with partial destruction of the former. A CD4+ immunophenotype of the neoplastic T cells with loss of one or more T-cell markers was demonstrated. In general, the patients were given more aggressive therapeutic regimens than those with conventional mycosis fungoides, and showed a trend towards more rapid disease progression. In conclusion, this case series confirms the distinct clinical and histological features of folliculotropic mycosis fungoides.
Assuntos
Micose Fungoide/diagnóstico , Pele/patologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Biomarcadores Tumorais/análise , Biópsia , Linfócitos T CD4-Positivos/imunologia , Estudos de Casos e Controles , Progressão da Doença , Intervalo Livre de Doença , Feminino , Hospitais Universitários , Humanos , Imuno-Histoquímica , Estimativa de Kaplan-Meier , Linfócitos do Interstício Tumoral/imunologia , Masculino , Pessoa de Meia-Idade , Micose Fungoide/imunologia , Micose Fungoide/mortalidade , Micose Fungoide/patologia , Micose Fungoide/terapia , Noruega , Valor Preditivo dos Testes , Sistema de Registros , Pele/imunologia , Fatores de TempoRESUMO
Allelic variants of the low-penetrance melanoma gene MC1R increase the risk of both melanoma and non-melanoma skin cancer. Common variants of the genes ASIP, TYR, and TYRP1, which regulate the melanogenic pathway, have also been shown to associate with melanoma. In this population-based study, we investigated SNPs of MC1R, ASIP, TYR, and TYRP1 as risk factors for development of multiple primary melanomas (MPM) in 388 Norwegian cases. The MPM patients had a significantly higher likelihood of carrying any MC1R variant than the control group of 420 blood donors [86.8 vs. 78.3%, OR = 1.73, and confidence intervals (CI) 1.18-2.52]. When MC1R variants were analyzed individually, Asp84Glu and Arg151Cys were significantly more frequent among the MPM cases than among the controls (OR = 5.77, CI 1.97-16.90, and OR = 1.80, CI 1.36-2.37, respectively). In addition, there was an allele dose-dependent increase in MPM risk for carriers of red hair color (RHC) MC1R variants. The AH haplotype of ASIP was also a significant risk factor for MPM development (OR = 1.72 and CI 1.12-2.49), whereas no association was observed for previously reported risk variants of the TYR and TYRP1 genes. In summary, by using a population-based material of high-risk melanoma cases, we demonstrate a significant effect of both MC1R RHC variants and an ASIP haplotype, but could not replicate an association with postulated risk SNPs of TYR and TYRP1.
Assuntos
Proteína Agouti Sinalizadora/genética , Melanoma/genética , Glicoproteínas de Membrana/genética , Monofenol Mono-Oxigenase/genética , Oxirredutases/genética , Receptor Tipo 1 de Melanocortina/genética , Neoplasias Cutâneas/genética , Adulto , Idoso , Feminino , Cor de Cabelo/genética , Haplótipos , Humanos , Masculino , Melanoma/epidemiologia , Pessoa de Meia-Idade , Noruega/epidemiologia , Razão de Chances , Polimorfismo de Nucleotídeo Único , Neoplasias Cutâneas/epidemiologiaRESUMO
BACKGROUND: The incidence of malignant melanoma in Norway is among the highest in the world and rising, with approximately 1 500 persons receiving the diagnosis annually. Correct surgical primary treatment cures 80-90%, while 10-20% experience relapses. The treatment of a metastatic malignant melanoma has changed considerably in the last 1-2 years as a result of clinical experience with new drugs. The current publication provides an updated overview of the treatment of malignant melanoma in Norway. METHOD: The article is based on a search in PubMed and on the authors' own research and clinical experience. RESULTS: After several decades with almost no change in the treatment of malignant melanoma, we have seen a positive development over the past couple of years. New treatment methods for malignant melanoma with distant spreading metastases have yielded favourable results in selected patients and are currently established in cancer departments in Norway. INTERPRETATION: Rapid and correct primary treatment is curing most patients with malignant melanoma. New drugs offer hope for selected patient groups with metastatic disease. Several new types of targeted treatment are being tested in clinical studies in Norway and elsewhere in the world.
Assuntos
Melanoma , Neoplasias Cutâneas , Humanos , Melanoma/diagnóstico , Melanoma/epidemiologia , Melanoma/patologia , Melanoma/terapia , Metástase Neoplásica , Noruega/epidemiologia , Neoplasias Cutâneas/diagnóstico , Neoplasias Cutâneas/epidemiologia , Neoplasias Cutâneas/patologia , Neoplasias Cutâneas/terapiaRESUMO
BACKGROUND: For complex diseases like cancer, pooled-analysis of individual data represents a powerful tool to investigate the joint contribution of genetic, phenotypic and environmental factors to the development of a disease. Pooled-analysis of epidemiological studies has many advantages over meta-analysis, and preliminary results may be obtained faster and with lower costs than with prospective consortia. DESIGN AND METHODS: Based on our experience with the study design of the Melanocortin-1 receptor (MC1R) gene, SKin cancer and Phenotypic characteristics (M-SKIP) project, we describe the most important steps in planning and conducting a pooled-analysis of genetic epidemiological studies. We then present the statistical analysis plan that we are going to apply, giving particular attention to methods of analysis recently proposed to account for between-study heterogeneity and to explore the joint contribution of genetic, phenotypic and environmental factors in the development of a disease. Within the M-SKIP project, data on 10,959 skin cancer cases and 14,785 controls from 31 international investigators were checked for quality and recoded for standardization. We first proposed to fit the aggregated data with random-effects logistic regression models. However, for the M-SKIP project, a two-stage analysis will be preferred to overcome the problem regarding the availability of different study covariates. The joint contribution of MC1R variants and phenotypic characteristics to skin cancer development will be studied via logic regression modeling. DISCUSSION: Methodological guidelines to correctly design and conduct pooled-analyses are needed to facilitate application of such methods, thus providing a better summary of the actual findings on specific fields.
Assuntos
Projetos de Pesquisa Epidemiológica , Predisposição Genética para Doença , Receptor Tipo 1 de Melanocortina , Neoplasias Cutâneas/genética , Luz Solar/efeitos adversos , Adulto , Estudos de Casos e Controles , Coleta de Dados/normas , Interpretação Estatística de Dados , Feminino , Hospitalização , Humanos , Modelos Logísticos , Masculino , Metanálise como Assunto , Fenótipo , Neoplasias Cutâneas/fisiopatologia , Neoplasias Cutâneas/secundário , FumarRESUMO
BACKGROUND: Patients with organ transplants have a significantly increased risk of skin cancer, especially squamous cell carcinoma, as a result of long-term treatment with immunosuppressive drugs. This paper provides a brief overview of the assumed underlying mechanisms. METHOD: The paper builds on relevant articles and studies identified in the course of many years of interest in immunopharmacology and skin cancer after organ transplantation. RESULTS: Reduced immunological tumour surveillance as a result of chronic immunosuppression has long been assumed to underlie the increased risk of skin cancer after organ transplants. Recent studies indicate that immunosuppressive drugs may also have specific carcinogenic effects. Aziatropine, which inhibits proliferation of lymphocytes, increases oxidative DNA damage caused by UV radiation. Ciclosporin and tacrolimus, which have an immunosuppressive effect by inhibiting calcineurin, promote malignant phenotypes in cell culture and tumour growth in mouse models. Calcineurin has proved to be necessary in order for p53 protein to have a protective effect against skin cancer. A relatively new class of immunosuppressive drugs, mTOR inhibitors, have antineoplastic properties and are associated with less risk of skin cancer. A number of randomised studies are currently in progress to see whether mTOR inhibitors can reduce the risk of skin cancer after organ transplantation. INTERPRETATION: Immunosuppressive drugs contribute to skin cancer after organ transplantation, either as a result of immunosuppression or through specific carcinogenic mechanisms. Immunosuppressive drugs with antineoplastic properties are now starting to be used.
Assuntos
Imunossupressores/efeitos adversos , Transplante de Órgãos/efeitos adversos , Neoplasias Cutâneas/etiologia , Antibióticos Antineoplásicos/uso terapêutico , Carcinoma de Células Escamosas/tratamento farmacológico , Carcinoma de Células Escamosas/etiologia , Carcinoma de Células Escamosas/imunologia , Humanos , Imunossupressores/farmacocinética , Imunossupressores/uso terapêutico , Fatores de Risco , Sirolimo/uso terapêutico , Neoplasias Cutâneas/tratamento farmacológico , Neoplasias Cutâneas/imunologia , Serina-Treonina Quinases TOR , Fatores de Tempo , Raios Ultravioleta/efeitos adversosRESUMO
BACKGROUND: Basal cell carcinoma may have a locally aggressive growth pattern. This type of cancer is often located on the face and is difficult to limit clinically. Normal excision and tumour destructive treatment often lead to recurrence of the tumour. Mohs surgery is a radical technique for removing this type of lesion. MATERIAL AND METHOD: This review article is based on articles identified by searching in PubMed with the search words "Mohs surgery" and "basal cell carcinoma", as well as personal experience. RESULTS: 10-15 % of all basal cell carcinomas have an aggressive growth pattern with sub clinical ramifications. Mohs surgery involves use of peroperative histological assessment of horizontal frozen sections, meaning that 100 % of the resection surface can be assessed. The objective is to reduce the risk of recurrence. Since the method saves tissue, simpler reconstruction can often be chosen. Mohs surgery is resource-demanding, but with the lower risk of recurrence, the method can be cost-effective when used for the correct indications. INTERPRETATION: Mohs surgery should be considered in basal cell carcinoma with an aggressive growth pattern on the face.
Assuntos
Carcinoma Basocelular/cirurgia , Neoplasias Faciais/cirurgia , Cirurgia de Mohs , Adulto , Carcinoma Basocelular/patologia , Neoplasias Faciais/patologia , Humanos , Cirurgia de Mohs/métodos , Recidiva Local de Neoplasia/prevenção & controle , Recidiva Local de Neoplasia/cirurgia , Neoplasias Nasais/patologia , Neoplasias Nasais/cirurgia , Fatores de Risco , Resultado do TratamentoRESUMO
BACKGROUND: A nation-wide Norwegian Patch Test Registry (NOLAR) was established in 2005 as a collaboration between six dermatology departments. International, multi-centre studies have documented great variability in the frequency of positive patch test reactions, considered as mainly due to heterogeneity of test populations. OBJECTIVES: To analyse the variability of positive test reactions by studying patch tests performed at the six collaborating departments, using standardized procedures. MATERIALS AND METHODS: Data from all patch tests (n = 2089) performed in 2007-2008 as registered in the NOLAR program. Differences between centres were analysed using Exact Pearson chi(2) test. RESULTS: Between the centres, positive test reactions (+, ++, or +++) varied significantly for 8 of the 26 allergens in the European Baseline Series. When considering strong reactions (++ or +++) only, the differences were statistically significant for six of these allergens, i.e. cobalt chloride, potassium dichromate, p-phenylenediamine, formaldehyde, paraben mix, and mercaptobenzothiazole. CONCLUSION: The results indicate regional differences in the prevalence of sensitization to certain allergens within the Norwegian population, although inter-observer differences cannot be ruled out as a factor.